Course InformationTherapautic Area: Cardiology
Format(s): Meeting Reporter, Downloadable Transcript
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: December 28, 2016- December 27, 2017
This CME program will focus on new and emerging therapeutic options in the management of patients with dyslipidemia that were discussed at the American Heart Association Annual Congress 2016 in New Orleans, Louisiana. The expert faculty will evaluate clinical trial data and the responsiveness to therapeutic agents. They will discuss the science behind new and emerging therapies, the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options.
Cardiologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
1. Describe guidelines consensus for LDL-C goal for dyslipidemia patients.
2. Examine outcomes data of PCSK9 inhibitors presented at AHA 2016.
3. Integrate new data into individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia.
James Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, NY
Michael Koren, MD
Jacksonville Center for Clinical Research